The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Cerebrovascular Accident

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cerebrovascular Accident


Psychiatry related information on Cerebrovascular Accident


High impact information on Cerebrovascular Accident

  • Cerebrovascular accident associated with testosterone therapy in a 21-year-old hypogonadal man [11].
  • The clot-busting drug tissue plasminogen activator (tPA) is currently the only FDA-approved therapy for acute stroke [12].
  • Intravenous tissue plasminogen activator (tPA) is used to treat acute stroke because of its thrombolytic activity and its ability to restore circulation to the brain [13].
  • Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial [14].
  • RESULTS: Across all states for all measures, the percentage of patients receiving appropriate care in the median state ranged from a high of 95% (avoidance of sublingual nifedipine for patients with acute stroke) to a low of 11% (patients with pneumonia screened for pneumococcal immunization status before discharge) [15].

Chemical compound and disease context of Cerebrovascular Accident

  • A pertinent question is what happens before this increase, because measures which prevent extracellular accumulation of glutamate could have potential for clinical use in, for example, management of acute stroke [16].
  • The capacity of various Sudan III-related chemicals to prevent DMBA-induced CA paralleled their capacity to prevent DMBA-induced adrenal apoplexy and mammary cancer [17].
  • The effects of intravenous glycerol and intravenous dextrose were compared using a double-blind trial in twenty-seven patients with acute stroke [18].
  • Double-blind randomised trial of intravenous glycerol in acute stroke [19].
  • Acute treatment of stroke. PASS group. Piracetam Acute Stroke Study [20].

Biological context of Cerebrovascular Accident


Anatomical context of Cerebrovascular Accident


Gene context of Cerebrovascular Accident


Analytical, diagnostic and therapeutic context of Cerebrovascular Accident


  1. Low-dose heparin prophylaxis against deep-vein thrombosis after acute stroke. Buruma, O.J., Wintzen, A.R., Briët, E. Lancet (1978) [Pubmed]
  2. Vascular toxicity associated with antineoplastic agents. Doll, D.C., Ringenberg, Q.S., Yarbro, J.W. J. Clin. Oncol. (1986) [Pubmed]
  3. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Beamer, N.B., Coull, B.M., Clark, W.M., Hazel, J.S., Silberger, J.R. Ann. Neurol. (1995) [Pubmed]
  4. Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. Endo, T., Scott, D.D., Stewart, S.S., Kundu, S.K., Marcus, D.M. J. Immunol. (1984) [Pubmed]
  5. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? To, C.H., Petri, M. Arthritis Rheum. (2005) [Pubmed]
  6. Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Shigeri, Y., Seal, R.P., Shimamoto, K. Brain Res. Brain Res. Rev. (2004) [Pubmed]
  7. Increased thromboxane biosynthesis is associated with poststroke dementia. van Kooten, F., Ciabattoni, G., Koudstaal, P.J., Grobbee, D.E., Kluft, C., Patrono, C. Stroke (1999) [Pubmed]
  8. Different linkage of depression to hypercortisolism early versus late after stroke. A 3-year longitudinal study. Aström, M., Olsson, T., Asplund, K. Stroke (1993) [Pubmed]
  9. An update on selected organic mental syndromes. Dickson, L.R., Ranseen, J.D. Hospital & community psychiatry. (1990) [Pubmed]
  10. Central nervous system ischemia after varicella infection and desmopressin therapy for enuresis. Wieting, J.M., Dykstra, D.D., Ruggiero, M.P., Robbins, G.B., Galusha, K. The Journal of the American Osteopathic Association. (1997) [Pubmed]
  11. Cerebrovascular accident associated with testosterone therapy in a 21-year-old hypogonadal man. Nagelberg, S.B., Laue, L., Loriaux, D.L., Liu, L., Sherins, R.J. N. Engl. J. Med. (1986) [Pubmed]
  12. Is tissue plasminogen activator a threat to neurons? Traynelis, S.F., Lipton, S.A. Nat. Med. (2001) [Pubmed]
  13. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Wang, Y.F., Tsirka, S.E., Strickland, S., Stieg, P.E., Soriano, S.G., Lipton, S.A. Nat. Med. (1998) [Pubmed]
  14. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. Sacco, R.L., DeRosa, J.T., Haley, E.C., Levin, B., Ordronneau, P., Phillips, S.J., Rundek, T., Snipes, R.G., Thompson, J.L. JAMA (2001) [Pubmed]
  15. Quality of medical care delivered to Medicare beneficiaries: A profile at state and national levels. Jencks, S.F., Cuerdon, T., Burwen, D.R., Fleming, B., Houck, P.M., Kussmaul, A.E., Nilasena, D.S., Ordin, D.L., Arday, D.R. JAMA (2000) [Pubmed]
  16. The early events of oxygen and glucose deprivation: setting the scene for neuronal death? Martin, R.L., Lloyd, H.G., Cowan, A.I. Trends Neurosci. (1994) [Pubmed]
  17. Suppression of 7,12-dimethylbenz[a]anthracene-induced chromosome aberrations in rat bone marrow cells after treatment with Sudan III and related azo dyes. Ito, Y., Maeda, S., Fujihara, T., Ueda, N., Sugiyama, T. J. Natl. Cancer Inst. (1982) [Pubmed]
  18. Double-blind trial of glycerol therapy in early stroke. Larsson, O., Marinovich, N., Barber, K. Lancet (1976) [Pubmed]
  19. Double-blind randomised trial of intravenous glycerol in acute stroke. Bayer, A.J., Pathy, M.S., Newcombe, R. Lancet (1987) [Pubmed]
  20. Acute treatment of stroke. PASS group. Piracetam Acute Stroke Study. De Deyn, P.P., Orgogozo, J.M., De Reuck, J. Lancet (1998) [Pubmed]
  21. Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Fagan, S.C., Gengo, F.M., Bates, V., Levine, S.R., Kinkel, W.R. Stroke (1988) [Pubmed]
  22. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group. Albers, G.W., Atkinson, R.P., Kelley, R.E., Rosenbaum, D.M. Stroke (1995) [Pubmed]
  23. Where and how should elderly stroke patients be treated? A randomized trial. Kaste, M., Palomäki, H., Sarna, S. Stroke (1995) [Pubmed]
  24. Spontaneous remission of primary hyperparathyroidism from parathyroid apoplexy. Nylen, E., Shah, A., Hall, J. J. Clin. Endocrinol. Metab. (1996) [Pubmed]
  25. Cardiopulmonary and arterial baroreflex-mediated control of forearm vasomotor tone is impaired after acute stroke. Robinson, T., Potter, J. Stroke (1997) [Pubmed]
  26. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. Schneider, A., Krüger, C., Steigleder, T., Weber, D., Pitzer, C., Laage, R., Aronowski, J., Maurer, M.H., Gassler, N., Mier, W., Hasselblatt, M., Kollmar, R., Schwab, S., Sommer, C., Bach, A., Kuhn, H.G., Schäbitz, W.R. J. Clin. Invest. (2005) [Pubmed]
  27. CSF enzymes in lacunar and cortical stroke. Donnan, G.A., Zapf, P., Doyle, A.E., Bladin, P.F. Stroke (1983) [Pubmed]
  28. Comparison of latex hypersensitivity among patients with neurologic defects. Konz, K.R., Chia, J.K., Kurup, V.P., Resnick, A., Kelly, K.J., Fink, J.N. J. Allergy Clin. Immunol. (1995) [Pubmed]
  29. Comparison of neurological scales and scoring systems for acute stroke prognosis. Muir, K.W., Weir, C.J., Murray, G.D., Povey, C., Lees, K.R. Stroke (1996) [Pubmed]
  30. Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles. Rupin, A., Martin, F., Vallez, M.O., Bonhomme, E., Verbeuren, T.J. Thromb. Haemost. (2001) [Pubmed]
  31. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. Albers, G.W., Bates, V.E., Clark, W.M., Bell, R., Verro, P., Hamilton, S.A. JAMA (2000) [Pubmed]
  32. The release of tumor necrosis factor-alpha is associated with ischemic tolerance in human stroke. Castillo, J., Moro, M.A., Blanco, M., Leira, R., Serena, J., Lizasoain, I., Dávalos, A. Ann. Neurol. (2003) [Pubmed]
  33. Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke. Slevin, M., Krupinski, J., Slowik, A., Kumar, P., Szczudlik, A., Gaffney, J. Stroke (2000) [Pubmed]
  34. Nitric oxide in the pathogenesis of vascular disease. Li, H., Förstermann, U. J. Pathol. (2000) [Pubmed]
  35. The frequency of epilepsy preceding stroke. Case-control study in 230 patients. Shinton, R.A., Gill, J.S., Zezulka, A.V., Beevers, D.G. Lancet (1987) [Pubmed]
  36. Animal model of human disease. Waterhouse-Friderichsen syndrome. Animal model: Acrylonitrile-induced adrenal apoplexy. Szabo, S., Reynolds, E.S., Kovacs, K. Am. J. Pathol. (1976) [Pubmed]
  37. Intravenous heparin for acute stroke: what can we learn from the megatrials? Swanson, R.A. Neurology (1999) [Pubmed]
  38. Common drugs may influence motor recovery after stroke. The Sygen In Acute Stroke Study Investigators. Goldstein, L.B. Neurology (1995) [Pubmed]
  39. Nimodipine and perfusion changes after stroke. Infeld, B., Davis, S.M., Donnan, G.A., Yasaka, M., Lichtenstein, M., Mitchell, P.J., Fitt, G.J. Stroke (1999) [Pubmed]
WikiGenes - Universities